Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
暂无分享,去创建一个
David Rey | L. Cuzin | P. Pradat | L. Cotte | M. Valantin | I. Poizot-Martin | A. Chéret | Marc-Antoine Valantin | Lise Cuzin | Isabelle Poizot-Martin | Eric Billaud | D. Rey | Claudine Duvivier | Alissa Naqvi | Véronique Obry-Roguet | Antoine Cheret | Christine Jacomet | Pascal Pugliese | Pierre Pradat | Laurent Cotte | C. Jacomet | P. Puglièse | C. Duvivier | E. Billaud | A. Naqvi | V. Obry-Roguet
[1] Christopher D Miller,et al. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients , 2015, Infectious Diseases and Therapy.
[2] Rebecca J. Cope,et al. Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. , 2015, AIDS patient care and STDs.
[3] S. Pol,et al. Treatment of acute hepatitis C in human immunodeficiency virus–infected patients: The HEPAIG study , 2010, Hepatology.
[4] G. Ioannou,et al. Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. , 2015, Epidemiologic reviews.
[5] T. Asselah,et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial , 2015, The Lancet.
[6] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[7] T. Heeren,et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] S. Khoo,et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection , 2014, Current opinion in infectious diseases.
[9] Christopher D Miller,et al. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection. , 2015, AIDS research and human retroviruses.
[10] Martin Fisher,et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. , 2009, Gastroenterology.
[11] C. Stedman,et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.
[12] K. Sherman,et al. HIV/hepatitis C coinfection natural history and disease progression. , 2011, Current opinion in HIV and AIDS.
[13] L. Cuzin,et al. A large French prospective cohort of HIV‐infected patients: the Nadis Cohort , 2009, HIV medicine.
[14] R. Weber,et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. , 2015, Journal of hepatology.
[15] Brad J. Wood,et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.
[16] J. Rockstroh,et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study , 2015, The Lancet.
[17] Aasld Idsa Hcv Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.
[18] F. Torriani,et al. The Hepatitis C Cascade of Care among HIV Infected Patients: A Call to Address Ongoing Barriers to Care , 2014, PloS one.
[19] Soriano,et al. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA , 2012 .
[20] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.
[21] A. Lok,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.
[22] B. Conway,et al. Who Needs Direct-Acting Antivirals for HCV? Challenges Faced in Advancing HCV Therapy for HIV–HCV-Coinfected Individuals , 2013, Antiviral therapy.
[23] V. Soriano,et al. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV , 2013, Annals of Internal Medicine.
[24] T. Pilot‐Matias,et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.
[25] N. Huo,et al. New progress on the treatment of hepatitis C: the interpretation of EASL Recommendations on Treatment of Hepatitis C 2015 , 2015 .
[26] E. Operskalski,et al. HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies , 2011, Current HIV/AIDS reports.
[27] V. Soriano,et al. Drug interactions with new hepatitis C oral drugs , 2015, Expert opinion on drug metabolism & toxicology.
[28] J. Mallolas,et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. , 2013, The Lancet. Infectious diseases.
[29] Qilong Yi,et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis , 2008, AIDS.
[30] D. Neau,et al. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] F. Dabis,et al. Burden of HIV and hepatitis C co‐infection: the changing epidemiology of hepatitis C in HIV‐infected patients in France , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[32] Brian L. Pearlman,et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.
[33] C. Umscheid,et al. The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis , 2014, PloS one.